Predictive Oncology Stock Performance
| POAI Stock | USD 1.11 0.01 0.91% |
Predictive Oncology holds a performance score of 9 on a scale of zero to a hundred. The company holds a Beta of 0.88, which implies possible diversification benefits within a given portfolio. Predictive Oncology returns are very sensitive to returns on the market. As the market goes up or down, Predictive Oncology is expected to follow. Use Predictive Oncology semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to analyze future returns on Predictive Oncology.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Predictive Oncology are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly conflicting basic indicators, Predictive Oncology demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Dividend Date 2019-10-29 | Last Split Date 2023-04-24 |
1 | Acquisition by Nuzum Charles Lee Sr of 6265 shares of Predictive Oncology subject to Rule 16b-3 | 01/03/2025 |
2 | Renovaroto Acquire Predictive Oncology in All-Stock Transaction | 01/06/2025 |
3 | Acquisition by Handley Daniel E of 2800 shares of Predictive Oncology at 0.35 subject to Rule 16b-3 | 01/10/2025 |
4 | Predictive Oncology Announces Planned European Launch of its Che | 01/16/2025 |
5 | Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. ... | 02/10/2025 |
6 | Whats Going On With Predictive Oncology Shares Tuesday | 02/18/2025 |
7 | Predictive Oncology announces registered direct offering shares fall | 02/19/2025 |
8 | Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology | 03/03/2025 |
9 | Acquisition by Raymond Vennare of 4600 shares of Predictive Oncology at 0.5164 subject to Rule 16b-3 | 03/05/2025 |
10 | Acquisition by St. Clair Gregory Sr of 6265 shares of Predictive Oncology subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 22.1 M |
Predictive |
Predictive Oncology Relative Risk vs. Return Landscape
If you would invest 69.00 in Predictive Oncology on December 23, 2024 and sell it today you would earn a total of 42.00 from holding Predictive Oncology or generate 60.87% return on investment over 90 days. Predictive Oncology is currently generating 1.3512% in daily expected returns and assumes 11.4402% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Predictive, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Predictive Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Predictive Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Predictive Oncology, and traders can use it to determine the average amount a Predictive Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1181
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | POAI | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.44 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.35 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Predictive Oncology is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Predictive Oncology by adding it to a well-diversified portfolio.
Predictive Oncology Fundamentals Growth
Predictive Stock prices reflect investors' perceptions of the future prospects and financial health of Predictive Oncology, and Predictive Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Predictive Stock performance.
| Return On Equity | -2.01 | ||||
| Return On Asset | -0.66 | ||||
| Operating Margin | (6.69) % | ||||
| Current Valuation | 7.29 M | ||||
| Shares Outstanding | 7.21 M | ||||
| Price To Book | 4.05 X | ||||
| Price To Sales | 5.39 X | ||||
| Revenue | 1.78 M | ||||
| Gross Profit | 681.38 K | ||||
| EBITDA | (13.18 M) | ||||
| Net Income | (13.98 M) | ||||
| Cash And Equivalents | 25.39 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 2.86 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | 0.29 X | ||||
| Cash Flow From Operations | (13.19 M) | ||||
| Earnings Per Share | (2.96) X | ||||
| Market Capitalization | 8 M | ||||
| Total Asset | 14.42 M | ||||
| Retained Earnings | (167.76 M) | ||||
| Working Capital | 6.13 M | ||||
About Predictive Oncology Performance
By evaluating Predictive Oncology's fundamental ratios, stakeholders can gain valuable insights into Predictive Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Predictive Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Predictive Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 326.90 | 387.01 | |
| Return On Tangible Assets | (0.89) | (0.93) | |
| Return On Capital Employed | (1.55) | (1.62) | |
| Return On Assets | (0.87) | (0.92) | |
| Return On Equity | (1.94) | (2.04) |
Things to note about Predictive Oncology performance evaluation
Checking the ongoing alerts about Predictive Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Predictive Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Predictive Oncology is way too risky over 90 days horizon | |
| Predictive Oncology may become a speculative penny stock | |
| Predictive Oncology appears to be risky and price may revert if volatility continues | |
| Predictive Oncology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.78 M. Net Loss for the year was (13.98 M) with profit before overhead, payroll, taxes, and interest of 681.38 K. | |
| Predictive Oncology currently holds about 25.39 M in cash with (13.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Latest headline from MacroaxisInsider: Acquisition by St. Clair Gregory Sr of 6265 shares of Predictive Oncology subject to Rule 16b-3 |
- Analyzing Predictive Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Predictive Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Predictive Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Predictive Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Predictive Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Predictive Oncology's stock. These opinions can provide insight into Predictive Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |